An interventional study of Acetazolamide 250 MG and Metolazone 2.5 MG in Heart Failure Acute and Decompensated Heart Failure, sponsored by Clinica Alemana de Santiago. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-18.
Sponsored by Clinica Alemana de Santiago · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing acetazolamide in Heart Failure — 6 open to participants now, 7 under way, 2 of them phase 3. Acetazolamide · Heart Failure.
Among the 14 studies testing acetazolamide in Heart Failure, this one has the largest planned enrollment, is one of 4 that started in 2024, is one of 2 with no phase, and was the 9th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →6 of the 14 studies testing acetazolamide in Heart Failure are open now, in 4 countries. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18+
Johannes Grand · Sites in Denmark
Ages 18+
Universitas Diponegoro · Sites in Indonesia
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18+
Lucrecia Maria Burgos
Ages 18+
By country, each count listing its studies:
Acetazolamide: first FDA approval 1953 (DIAMOX). What it is approved for, and how studies give it, is on its page →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,050 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 66 across the 14 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 14 has an industry lead sponsor. The 10 most frequent:
Clinica Alemana de Santiago is the lead sponsor of 11 studies on the registry; 7 are open to participants now.
Clinica Alemana de Santiago has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
3 of the studies testing acetazolamide in Heart Failure that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07593612Lucrecia Maria BurgosTACTIC-HF: Sequential Diuretic Strategies in Ambulatory Worsening Heart Failure | 2027-01-15 |
| NCT07372040Tanta UniversityAdd-on Diuretics in Acute Decompensated Heart Failure | 2027-02-01 |
| NCT06273397Clinica Alemana de SantiagoAcetazolamide or Metolazone in Acute Heart Failure | 2027-03-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies testing acetazolamide in Heart Failure, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Impact of Acute Heart Failure:
According to the World Health Organization (WHO), approximately 26 million people suffer from Heart Failure (HF), with a mortality rate of up to 50% within five years of diagnosis. Acute Heart Failure (AHF) exacerbations, leading to hospitalization, are common and represent the primary cause of hospital admissions in those over 65. Effective decongestion during hospitalization is crucial, as failure to achieve it doubles the risk of rehospitalization and mortality, incurring significant healthcare costs.
Use of Diuretics in Acute Heart Failure:
Diuretics, particularly loop diuretics like furosemide, are a cornerstone in managing AHF by inducing natriuresis and achieving decongestion. Clinical experience supports their use, though limited clinical trials exist. Pharmacological concepts guide their administration, emphasizing intravenous delivery in high doses and adjusting subsequent doses based on decongestive efficacy. Additionally, sequential tubular blockade with other diuretics like metolazone and acetazolamide is explored to enhance decongestion.
Use of Metolazone and Acetazolamide:
Sequential tubular blockade, using metolazone and acetazolamide in conjunction with furosemide, aims to achieve rapid and effective decongestion. While metolazone targets the distal tubule, inhibiting sodium-chloride channels, acetazolamide affects proximal tubular function. Studies like ADVOR (acetazolamide) and CLOROTIC (thiazide-like diuretic) demonstrate the potential benefits of combining these diuretics for quicker decongestion but with potential risks (in the case of Hydrochlorothiazide).
Outcomes Measured by Major Studies:
Recent studies assessing decongestion in AHF reveal a lack of uniformity in outcome selection. The primary focus should be on reducing rehospitalizations and post-discharge mortality by achieving effective decongestion. The ADVOR study, using a simple congestion score based on clinical and imaging criteria, underscores the importance of reaching a congestion score of 0 or 1 promptly.
Congestion Monitoring:
Monitoring diuretic treatment solely based on clinical aspects may not capture subclinical congestion, necessitating biochemical and imaging parameters. The ACME-AHF trial proposes a diagnostic score integrating clinical and imaging aspects to evaluate congestion status. Secondary outcomes include cumulative diuresis, weight loss, diuretic efficiency, and natriuresis, with a focus on natriuresis as a reliable physiological parameter for decongestion.
Aim of the study:
The ACME-AHF trial is designed to compare the efficacy and safety of two diuretic combination strategies: acetazolamide with furosemide and metolazone with furosemide. The primary objective is to relieve congestion, assessed using a congestion score, within the first three days of treatment during an hospitalization for acute heart failure.
After inclusion in the study and signing the informed consent, the patient will be randomized into one of the following three intervention groups:
Metolazone or acetazolamide will be administered in fixed doses for a total of 3 doses (D0, D1, and D2) - at admission (D0), on the morning of the second day (D1), and on the morning of the third day (D2).
The use of intravenous furosemide will follow a protocol for dose and frequency of administration. Its dose should not be modified before D2. On D2, modification is allowed according to the protocol (details later).
In cases of major adverse events only, the local practitioner may suspend these therapies (as indicated later).
The study is driven by a clinical outcome based on a congestion score. The primary outcome will assess the ability to achieve effective decongestion (score 0 - 1) for each of the three interventions over 3 days. The primary outcome will be considered achieved if a score of 0 - 1 is reached on D1, D2, or D3, without requiring escalation of diuretic therapy on D2. The congestion score consists of 3 clinical parameters (edema, jugular venous distension, lung crepitations), one radiological parameter (pleural effusion on X-ray), and one ultrasonographic parameter (LUS: B-line count in 4 zones). A score is assigned based on the intensity of each parameter, with 0 and 1 considered as a score indicative of complete decongestion.
The key determinant on D0, D1, and D2, guiding whether the intervention continues or stops, is the persistence of congestion. The intervention should continue for those with a congestion score of 2 or more during the first assessment of the day. If the congestion score is 0 or 1, the intervention is suspended, and the patient should transition to oral furosemide (in preparation for hospital discharge).
Here is the detailed procedure for each day of intervention (total 3 days, closing on the third morning of hospitalization or D3):
Additional recommendations for the intervention include:
Situations for Intervention Cessation: (protocol termination and AE reporting)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active comparator arm with intravenous furosemide dosing based on glomerular filtration rate (protocol).
Drug: Furosemide Injection
Experimental arm number 1 corresponds to oral acetazolamide 250mg (once daily) in combination with furosemide according to the protocol.
Drug: Acetazolamide 250 MG · Drug: Furosemide Injection
Experimental arm number 2 corresponds to oral metolazone 2.5mg (once daily) in combination with furosemide according to the protocol.
Drug: Metolazone 2.5 MG · Drug: Furosemide Injection
Acetazolamide 250mg orally per day plus furosemide as per protocol. The intervention is administered on the day of hospital admission and for two consecutive mornings. The total intervention consists of 3 doses. The intervention is discontinued on the third morning. The calculation of the congestion score is performed every morning until the third morning. If complete decongestion is achieved, the primary outcome will be considered fulfilled.
Metolazone 2.5mg orally per day plus furosemide as per protocol. The intervention is administered on the day of hospital admission and for two consecutive mornings. The total intervention consists of 3 doses. The intervention is discontinued on the third morning. The calculation of the congestion score is performed every morning until the third morning. If complete decongestion is achieved, the primary outcome will be considered fulfilled.
Intravenous furosemide in a double daily dose. The dosage is determined by a predefined table based on the admission renal function and the outpatient dose prior to admission. In general terms, for patients with an estimated glomerular filtration rate above 60 ml/min/1.73m² or those experiencing heart failure debut, the dose will be 1x the outpatient dose. For those with a glomerular filtration rate below 60 ml/min/1.73m², the dose will be 2x the outpatient dose. The dosing protocol for this arm also serves as guidance for furosemide in the intervention arms.
Treatment success
Complete decongestion by the third morning without requiring escalation in diuretic therapy (by the second morning).
Time frame: 4 days
Mortality
All-cause mortality during the first 3 months after start of the study
Time frame: 3 months
Worsening Heart Failure
Readmission for Heart Failure or Urgent visit for Heart Failure during the first 3 months after start of the study
Time frame: 3 months
Cumulative 24-hour Natriuresis
Natriuresis measured on the second day
Time frame: Day 2
Cumulative weight loss
Cumulative weight loss by the third morning
Time frame: 4 days
Subclinical congestion
Congestion score will be the score used in the study to evaluate the primary outcome. The calculated scores can range from 0 to 12 points, with 0 indicating absence of congestion and 12 representing the highest degree of congestion. The primary outcome will be defined as achieving a score of 0 or 1 and also having absence of B-lines in the lung ultrasound (negative LUS criterion). In this secondary outcome, the presence of subclinical congestion will be evaluated, which is defined as a congestion score of 0 or 1 but with a positive LUS.
Time frame: 4 days
Change in Hematocrit value
Change in Hematocrit
Time frame: 4 days
Change in NT-proBNP concentration
Change in NT-proBNP
Time frame: 4 days
Change in CA125 value
Change in CA125
Time frame: 4 days
Any adverse event
Any adverse clinical event related to intervention during the first 3 months after start of the study
Time frame: 3 months
Changes in pH value
Change in pH over the specified time period
Time frame: 4 days
Change in plasma electrolyte values
Change in plasma concentration of sodium, potassium, and chloride
Time frame: 4 days
No study locations are listed for this record.
Plan to share: Undecided
Start is estimated for May 2024; primary completion for Mar 2027, 34 months later.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 34 months is above that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Acetazolamide · Metolazone
Clinica Alemana de Santiago